Gene Therapy Vectors Articles & Analysis
30 news found
Caroline Man Xu, Co-founder and CEO of ViGeneron said:” Recombinant AAV vectors are an established platform for effective gene therapies today. ...
The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. ...
Gene expression and therapy involves the introduction of foreign nucleic acids into target cells to modify or compensate for gene defects, thereby treating diseases such as cancer, diabetes, autoimmune diseases, and infectious diseases. However, when exposed nucleic acids are removed fast, resulting in low rates of nonspecific biodistribution and ...
This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery system for inserting good genes into cells. ...
The calf was administered the AAV9 gene therapy vector at 40 hours of life. Following AAV therapy, biomarker measurements indicated a significant restoration of the missing enzymatic activity. ...
About RP-L201 RP-L201 is an investigational gene therapy product being developed for severe Leukocyte Adhesion Deficiency-I (LAD-I). The therapy consists of hematopoietic stem cells from the patient that have been genetically modified with a lentiviral vector to contain a functional copy of the ITGB2 gene. ...
(Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the opening of its new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene ...
NRC researchers are re-engineering AAV-LPL using new adeno-associated viral (AAV) derived vectors to advance the LPLD gene therapy originally developed at the University of British Columbia. ...
The product manager of the company is excited to launch the Gene Therapy Products Characterization service to help clients overcome the challenges of gene therapy analytical development, which include characterization, quality control, and the need to meet increasingly demanding regulatory expectations. Gene ...
“We are proud of our commitment to serving the scientific community, in particular cell and gene therapy developers, with the highest quality viral vectors” said Dieter Lingelbach, Chief Operations Officer at SIRION Biotech. ...
Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene ...
Together, with our talented team, we are excited to move to the next chapter of Neurona’s evolution, bringing the company’s pioneering cell therapies to people suffering from chronic disorders of the nervous ...
” “The partnership with Carina Biotech marks a significant milestone for us to facilitate the furtherance of gene therapies. We look forward to supporting Carina in the successful development of its LGR5 CAR-T cells,” said Dr Ang Peng Tiam, Chairman of CellVec and Medical Director of Parkway Cancer Centre. ...
These expansions in Greenville, NC; Monza and Ferentino, IT; and Swindon, UK increase manufacturing capacity for sterile liquid and lyophilized filling, and pre-filled syringes. Demand for Cell & Gene Therapy Thermo Fisher's continued investment in cell and gene therapy services is focused on delivering manufacturing ...
Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. ...
Accelerating Demand for Cell & Gene Therapy Thermo Fisher's continued investment in cell and gene therapy services is focused on delivering manufacturing expertise and capacity to support customers at key points along the pathway to commercialization. Thermo Fisher will open its new cGMP plasmid DNA manufacturing facility ...
A new media panel, gene kit and advanced purification resins help reduce manufacturing costs while increasing the viability of gene therapies as treatment options for patients. AAV is a non-pathogenic virus with the ability to infect cells at various stages of growth, and has become a preferred "viral vector" for delivering ...
Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced the company has entered a research collaboration with Children’s Medical Research Institute (“CMRI”) in Australia to develop next-generation clinical capsids, the protein shells ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. ...